GERN - Geron Corporation logo

Geron Corporation

GERN

Geron Corporation develops therapeutics for oncology, focusing on hematologic malignancies. Its pipeline includes RYTELO for myelodysplastic syndromes and several candidates in various clinical trial phases for related blood cancers.

โš•๏ธ Healthcare NASDAQ Listed 1996 $ USD
$1,000 invested 30 years ago โ†’$191today

Score Overview

1 Year
Score
Net Growth18.52%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth11.25%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.9
Net Growth39.80%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth146x
Rev Trend67%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-136.63%
Net Trend50%
Net Income Consistency
Rev Growth33x
Rev Trend50%
Revenue Consistency
20 Years
Score2.9
Net Growth-122.84%
Net Trend50%
Net Income Consistency
Rev Growth62x
Rev Trend44%
Revenue Consistency
30 Years
Score
Net Growth-4x
Net Trend57%
Net Income Consistency
Rev Growth38x
Rev Trend39%
Revenue Consistency
All Time
Score
Net Growth-4x
Net Trend57%
Net Income Consistency
Rev Growth38x
Rev Trend39%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Geron Corporation has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. GERN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 1.24โ€”
1 Year2025-09-29
$ 1.31-5.34%
5 Years2021-09-29
$ 1.38-10.14%
10 Years2016-09-29
$ 2.20-43.64%
20 Years2006-09-29
$ 5.92-79.07%
30 Years1996-09-27
$ 6.50-80.91%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 204M-$ 69M$ 300M
2025$ 183M-$ 85M$ 359M
2024$ 76M-$ 174M$ 406M
2023-$ 184M$ 333M
2022$ 596K-$ 141M$ 172M
2021$ 1M-$ 116M$ 183M
2020$ 253K-$ 75M$ 196M
2019$ 460K-$ 63M$ 139M
2018$ 1M-$ 27M$ 163M
2017$ 1M-$ 27M$ 94M
2016$ 6M-$ 29M$ 115M
2015$ 36M$ 114M
2014$ 1M-$ 35M$ 151M
2013$ 1M-$ 38M$ 65M
2012$ 2M-$ 68M$ 96M
2011$ 2M-$ 96M$ 121M
2010$ 3M-$ 111M$ 186M
2009$ 1M-$ 70M$ 111M
2008$ 2M-$ 62M$ 162M
2007$ 7M-$ 36M$ 206M
2006$ 3M-$ 31M$ 213M
2005$ 290K-$ 33M$ 190M
2004$ 1M-$ 80M$ 119M
2003$ 1M-$ 29M$ 109M
2002$ 1M-$ 33M$ 46M
2001$ 3M-$ 42M$ 68M
2000$ 6M-$ 45M$ 33M
1999$ 5M-$ 46M$ 7M
1998$ 6M-$ 10M$ 16M
1997$ 7M-$ 9M$ 4M
IPO1996$ 5M-$ 10M$ 12M
GERN - Geron Corporation logo

Geron Corporation fundamental performance

Between 2020 and 2025, revenue grew from $ 253K to $ 183M and net income went from -$ 75M to -$ 85M. Revenue increased in 3 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 36M to $ 183M. Revenue increased in 5 of those 10 years; net income in 5.

Geron Corporation currently holds a 20-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.

Membership

Explore GERN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies